Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Closed due to poor accrual.

Conditions

Hepatocellular Carcinoma
Hepatocellular Cancer
Hepatoma
Liver Cancer

Interventions

DRUG: Sorafenib
RADIATION: Conventional fractionation (2 Gy per day) external beam radiation therapy

Sponsor

Medical College of Wisconsin